NASDAQ:IMGN - ImmunoGen Stock Price, Forecast & News

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings data on Friday, November, 1st. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. The biotechnology company earned $13.30 million during the quarter, compared to analyst estimates of $10.38 million. The business's quarterly revenue was up 22.0% compared to the same quarter last year. During the same period last year, the business earned ($0.32) earnings per share. View ImmunoGen's Earnings History.

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, February 14th 2020. View Earnings Estimates for ImmunoGen.

9 brokerages have issued 1-year price objectives for ImmunoGen's shares. Their forecasts range from $2.50 to $9.00. On average, they anticipate ImmunoGen's share price to reach $4.28 in the next twelve months. This suggests that the stock has a possible downside of 6.1%. View Analyst Price Targets for ImmunoGen.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ImmunoGen.

News headlines about IMGN stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ImmunoGen earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for ImmunoGen.

ImmunoGen saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 12,550,000 shares, an increase of 14.2% from the December 31st total of 10,990,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the short-interest ratio is currently 5.2 days. Currently, 8.5% of the company's stock are short sold. View ImmunoGen's Current Options Chain.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Pfizer (PFE), Micron Technology (MU), NVIDIA (NVDA), Exelixis (EXEL), Nektar Therapeutics (NKTR), Seattle Genetics (SGEN), Alibaba Group (BABA), Gilead Sciences (GILD) and Synergy Pharmaceuticals (SGYP).

ImmunoGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include California Public Employees Retirement System (0.21%) and Arden Trust Co (0.01%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View Institutional Ownership Trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including Arden Trust Co. Company insiders that have sold ImmunoGen company stock in the last year include Mark J Enyedy and Thomas Ryll. View Insider Buying and Selling for ImmunoGen.

IMGN stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. View Insider Buying and Selling for ImmunoGen.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IMGN stock can currently be purchased for approximately $4.56.

ImmunoGen has a market capitalization of $682.61 million and generates $53.82 million in revenue each year. The biotechnology company earns $-168,840,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.View Additional Information About ImmunoGen.

The official website for ImmunoGen is http://www.immunogen.com/.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]